For the evaluation of anti-cancer features of CAP, treatment of cells that feature a favorable MGMT status and are highly susceptible to TMZ (LN229, U87MG), and in comparison cells that have an unfavorable MGMT status and are resistant to TMZ (LN18) (fig. This evidence concerns the gene MGMT and cancer.